MAST CELLS AS NOVEL EFFECTOR CELLS IN THE PATHOGENESIS OF CHRONIC GRAFT-VERSUS-HOST DISEASE

Ethan Strattan
Hematopoietic stem cell transplantation (HSCT) is most commonly a treatment for inborn defects of hematopoiesis or acute leukemias. Widespread use of HSCT, a potentially curative therapy, is hampered by onset of graft-versus-host-disease (GVHD), a condition wherein the donor cells recognize the patient tissues as non-self. GVHD can manifest anywhere from weeks to decades post-transplant and is classified as either acute or chronic GVHD, both of which are significant causes of transplant-related morbidity and mortality. However,...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.